Kalaris Therapeutics (KLRS) Non Operating Income (2024 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Non Operating Income of $977000.0 for Q1 2026, up 518.35% year-over-year from $158000.0 in Q1 2025, and up 21.67% quarter-over-quarter from $803000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Non Operating Income (2024 - 2026) Analysis & Trends
Kalaris Therapeutics' Non Operating Income history runs 3 years deep, the most recent figure standing at $977000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 518.35% year-over-year to $977000.0; the TTM figure through Mar 2026 stood at $3.5 million (up 121.5% YoY), while the FY2025 annual figure was $2.7 million, up 115.57% from the prior year.
- Non Operating Income for Q1 2026 stood at $977000.0, up from $803000.0 in the prior quarter.
- The five-year high for Non Operating Income was $977000.0 in Q1 2026, with the low at -$14.9 million in Q4 2024.
- The 3-year median for Non Operating Income is $158000.0 (2025), against an average of -$1.5 million.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income jumped 105.39% in 2025, then jumped 518.35% in 2026.
- Kalaris Therapeutics' Non Operating Income stood at -$14.9 million in 2024, then surged by 105.39% to $803000.0 in 2025, then increased by 21.67% to $977000.0 in 2026.
- Business Quant data shows KLRS's Non Operating Income at $977000.0 in Q1 2026, $803000.0 in Q4 2025, and $847000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | 871,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 871,000.00 |
| Mar 31, 2026 | 977,000.00 |
| Dec 31, 2025 | 803,000.00 |
| Sep 30, 2025 | 847,000.00 |
| Jun 30, 2025 | 906,000.00 |
| Mar 31, 2025 | 158,000.00 |
| Dec 31, 2024 | -14.89 Mn |
| Sep 30, 2024 | -235,000.00 |
| Jun 30, 2024 | -1.46 Mn |
| Mar 31, 2024 | -844,000.00 |